Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma

Human Pathology

Volumn 38, Issue 3, 2007, Pages 453-461

  Parker, Alexander Scott ^a   Lohse, Christine M ^a   Wu, Kevin ^a   Kreinest, Pamela ^a   Copland, John A ^a   Hilton, Tracy ^a   Wehle, Michael ^a   Cheville, John C ^a   Blute, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cohort; Renal cancer; Survival; Transforming growth factor beta type II receptor

Indexed keywords

RECEPTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLEAR CELL CARCINOMA; COHORT ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33846858645     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.08.029     Document Type: Article

References (48)

1. Curti B.D. Renal cell carcinoma. JAMA 292 (2004) 97-100
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
3. Kattan M.W., Reuter V., Motzer R.J., Katz J., and Russo P. A postoperative nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
4. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
5. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. J Urol 168 (2002) 2395-2400
6. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97 (2003) 1663-1671
7. Atkins M.B., Avigan D.E., Bukowski R.M., et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 10 18 Pt 2 (2004) 6277S-6281S
8. Lam J.S., Shvarts O., Leppert J.T., Figlin R.A., and Belldegrun A.S. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urology 173 (2005) 1853-1862
9. Attisano L., and Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 296 (2002) 1646-1647
10. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
11. Glick A.B. TGFbeta1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol Ther 3 (2004) 276-283
12. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425 (2003) 577-584
13. Gold L.I. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 10 (1999) 303-360
14. Massague J., and Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19 (2000) 1745-1754
15. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268 (1995) 1336-1338
16. Myeroff L.L., Parsons R., Kim S.J., Hedrick L., Cho K.R., Orth K., et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55 (1995) 5545-5547
17. Parsons R., Myeroff L.L., Liu B., Willson J.K., Markowitz S.D., Kinzler K.W., et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55 (1995) 5548-5550
18. Garrigue-Antar L., Muñoz-Antonia T., Antonia S.J., et al. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 55 (1995) 3982
19. Park K., Kim S.J., Bang Y.J., Kim N.K., Roberts A.B., et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A 91 (1994) 8772-8776
20. Zhao S., Venkatasubbarao K., Li S., and Freeman J.W. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta type II receptor expression in human pancreatic cancer cells. Cancer Res 63 (2003) 2624-2630
21. Zhao H., Shiina H., Greene K.L., et al. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 104 (2005) 44-52
22. Osada H., Tatematsu Y., Sugito N., Horio Y., and Takahashi T. Histone modification in the TGFbeta RII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. Mol Carcinog 44 (2005) 233-241
23. Ammanamanchi S., Tillekeratne M.P., Ko T.C., and Brattain M.G. Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells. Cancer Res 64 (2004) 2509-2515
24. Sun L., Wu G., Willson J.K., Zborowska E., Yang J., Rajkarunanayake I., et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269 (1994) 26449-26455
25. Wang J., Sun L., Myeroff L., Wang X., Gentry L.E., Yang J., et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270 (1995) 22044-22049
26. Copland J.A., Luxon B.A., Ajani L., et al. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 22 (2003) 6109-6118
27. Elliott R.L., and Blobe G.C. Role of transforming growth factor beta in human cancer. J Clin Oncol 23 (2005) 2078-2093
28. Oft M., Heider K.H., and Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8 (1998) 1243-1252
29. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100 (2003) 8621-8623
30. Lohse C.M., Blute M.L., Zincke H., et al. Comparison of standardized and non-standardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 118 (2003) 877-886
31. Sengupta S., Lohse C.M., Leibovich B.C., et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104 (2005) 511-520
32. American Joint Committee on Cancer. AJCC Cancer staging manual. 6th ed. (2002), Springer-Verlag, New York (NY)
33. Ficarra V., Martignoni G., Lohse C., et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 175 (2006) 1235-1239
34. Lohse C.M., and Cheville J.C. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 25 (2005) 433-464
35. Blute M.L., Leibovich B.C., Lohse C.M., Cheville J.C., and Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumor thrombus. BJU Int 94 (2004) 33-41
36. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 34 (1972) 187-220
37. Figlin R., Pierce W.C., Kaboo R., et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158 (1997) 740-745
38. Akhurst R.J. TGF-beta antagonists: why suppress a tumor suppressor?. J Clin Invest 109 (2002) 1533-1536
39. Wakefield L.M., and Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12 (2002) 22-29
40. de Caestecker M.P., Piek E., and Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92 (2000) 1388-1402
41. Akhurst R.J., and Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11 (2001) S44-S51
42. Buck M.B., Fritz P., Dippon J., Zugmaier G., and Knabbe C. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 10 (2004) 491-498
43. Takanami I., Tanaka F., Hashizume T., and Kodaira S. Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol 64 (1997) 262-267
44. Wagner M., Kleeff J., Friess H., Buchler M.W., and Korc M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19 (1999) 370-376
45. Watanabe T., Wu T.T., Catalano P.J., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 (2001) 1196-1206
46. Miyajima A., Asano T., Seta K., Asano T., Kakoi N., and Hayakawa M. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology 61 (2003) 1072-1077
47. Dumont N., and Arteaga C.L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3 (2003) 531-536
48. Iyer S., Wang Z.G., Akhtari M., Zhao W., and Seth P. Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 4 (2005) 261-266